Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery

Theranostics

Volumn 5, Issue 1, 2015, Pages 43-61

  Yang, Emmy ^a   Qian, Weiping ^a   Cao, Zehong ^a   Wang, Liya ^a   Bozeman, Erica N ^a   Ward, Christina ^a   Yang, Bin ^b   Selvaraj, Periasamy ^a   Lipowska, Malgorzata ^a   Wang, Y Andrew ^c   Mao, Hui ^a   Yang, Lily ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHENGDU WOMEN S AND CHILDREN S CENTRAL HOSPITAL   (China)

^c OCEAN NANOTECH LLC   (United States)

Author keywords

Antibody; Immune response; Nanoparticle delivery; Nanoparticles; Targeting ligands; Tumor imaging

Indexed keywords

DOXORUBICIN; LIGAND; MACROGOL; MAGNETIC IRON OXIDE NANOPARTICLE; NANOPARTICLE; RECOMBINANT PROTEIN; THERANOSTIC NANOPARTICLE; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FEMALE; IMMUNOGENICITY; MACROPHAGE; MOUSE; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; HUMAN; IMMUNOLOGY; PROCEDURES; SCID MOUSE;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, SCID; NANOPARTICLES;

EID: 84924327403     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10350     Document Type: Article

References (59)

1. Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464: 1067-70.
2. Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011; 121: 2768-80.
3. Lee JH, Huh YM, Jun Y, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007; 13: 95-9.
4. Nasongkla N, Bey E, Ren JM, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006; 6: 2427-30.
5. Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012; 4: 128ra39.
6. Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013; 7: 2078-89.
7. Bhirde AA, Liu G, Jin A, et al. Combining portable Raman probes with nanotubes for theranostic applications. Theranostics. 2011; 1: 310-21.
8. Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010; 18: 1650-6.
9. Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32: 2141-8.
10. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008; 49: 1371-9.
11. Han H, Davis ME. Single-antibody, targeted nanoparticle delivery of camptothecin. Mol Pharm. 2013; 10: 2558-67.
12. Kelly KA, Bardeesy N, Anbazhagan R, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 2008; 5: e85.
13. Yang L, Peng XH, Wang YA, et al. Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer. Clin Cancer Res. 2009; 15: 4722-32.
14. Thakor AS, Luong R, Paulmurugan R, et al. The fate and toxicity of Raman- active silica-gold nanoparticles in mice. Sci Transl Med. 2011; 3: 79ra33.
15. Dobrovolskaia MA, Aggarwal P, Hall JB, et al. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008; 5: 487-95.
16. Moore A, Medarova Z, Potthast A, et al. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 2004; 64: 1821-7.
17. Kievit FM, Stephen ZR, Veiseh O, et al. Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano. 2012; 6: 2591-601.
18. Zhou Y, Drummond DC, Zou H, et al. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor- expressing tumor cells. J Mol Biol. 2007; 371: 934-47.
19. Yang L, Mao H, Wang YA, et al. Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging. Small. 2009; 5: 235-43.
20. Sakamoto JH, Smith BR, Xie B, et al. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents. Technol Cancer Res Treat. 2005; 4: 627-36.
21. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001; 28: 13-9.
22. Schier R, Bye J, Apell G, et al. Isolation of high-affinity monomeric human Anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol. 1996; 255: 28-43.
23. Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods. 1999; 231: 249-60.
24. Steffen AC, Orlova A, Wikman M, et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging. 2006; 33: 631-8.
25. Kramer-Marek G, Gijsen M, Kiesewetter DO, et al. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med. 2012; 53: 629-37.
26. Peng XH, Wang Y, Huang D, et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano. 2011; 5: 9480-93.
27. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3: 932-43.
28. Han B, Nakamura M, Mori I, et al. Urokinase-type plasminogen activator system and breast cancer. Oncol Rep. 2005; 14: 105-12.
29. Yang L, Mao H, Cao ZH, et al. Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles. Gastroenterology. 2009; 136: 1514-25.
30. Yang L, Sajja HK, Cao Z, et al. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. Theranostics. 2013; 4: 106-18.
31. Li R, Zheng K, Hu P, et al. A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics. 2014; 4: 642-59.
32. Moore A, Weissleder R, Bogdanov A, Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging. 1997; 7: 1140-5.
33. Cruz LJ, Rueda F, Cordobilla B, et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol Pharm. 2011; 8: 104-16.
34. Lutsiak ME, Kwon GS, Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol. 2006; 58: 739-47.
35. Moon JJ, Suh H, Li AV, et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A. 2012; 109: 1080-5.
36. Patel J, Galey D, Jones J, et al. HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. Vaccine. 2006; 24: 3564-73.
37. Sloat BR, Sandoval MA, Hau AM, et al. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release. 2010; 141: 93-100.
38. Stano A, van der Vlies AJ, Martino MM, et al. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine. 2011; 29: 804-12.
39. Roy A, Singh MS, Upadhyay P, et al. Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach. Mol Pharm. 2010; 7: 1778-88.
40. Wadhwa S, Jain A, Woodward JG, et al. Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responses. Eur J Pharm Biopharm. 2012; 80: 315-22.
41. Chen H, Wang L, Yeh J, et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials. 2010; 31: 5397-407.
42. Yu T, Hubbard D, Ray A, et al. In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release. 2012; 163: 46-54.
43. Shenoy D, Little S, Langer R, et al. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor- targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm Res. 2005; 22: 2107-14.
44. Bartneck M, Keul HA, Singh S, et al. Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano. 2010; 4: 3073-86.
45. Cole AJ, David AE, Wang J, et al. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials. 2011; 32: 6291-301.
46. Dhar S, Kolishetti N, Lippard SJ, et al. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A. 2011; 108: 1850-5.
47. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm. 2008; 354: 56-62.
48. Pham CT, Mitchell LM, Huang JL, et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem. 2011; 286: 123-30.
49. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005; 216: 106-21.
50. Yu WW, Falkner JC, Yavuz CT, et al. Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem Commun. 2004;: 2306-7.
51. Chen K, Xie J, Xu H, et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials. 2009; 30: 6912-9.
52. Zhou Z, Chen H, Lipowska M, et al. A dual-modal magnetic nanoparticle probe for preoperative and intraoperative mapping of sentinel lymph nodes by magnetic resonance and near infrared fluorescence imaging. J Biomater Appl. 2013; 28: 100-11.
53. Yang L CZ, Sajja HK, Mao H, Wang L, Geng H, Xu H, Jiang T, Wood WC, Nie S, Wang YA. Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging. J Biomed Nanotechnol. 2008; 4: 1-11.
54. Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005; 51: 2415-8.
55. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1992; 176: 1693-702.
56. Wolenski M, Cramer SO, Ehrlich S, et al. Expression of CD83 in the murine immune system. Med Microbiol Immunol. 2003; 192: 189-92.
57. Lechmann M, Shuman N, Wakeham A, et al. The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo. Proc Natl Acad Sci U S A. 2008; 105: 11887-92.
58. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002; 20: 621-67.
59. Roland CR, Walp L, Stack RM, et al. Outcome of Kupffer cell antigen presentation to a cloned murine Th1 lymphocyte depends on the inducibility of nitric oxide synthase by IFN-gamma. J Immunol. 1994; 153: 5453-64.